Pfizer Halts Phase III Study Of Sutent In Advanced Breast Cancer
This article was originally published in Pharmaceutical Approvals Monthly
Pfizer's efforts to gain a monotherapy indication for its oncologic Sutent in advanced breast cancer may have been derailed by a failed single-agent trial, but the company still has several Phase III studies of Sutent in combination with various chemotherapies that could give it an entry into the breast cancer market
You may also be interested in...
Phase III study, halted for efficacy, tested the tyrosine kinase inhibitor in a disease type that strikes about 30 to 50 patients per million of the total afflicted.
New head of out-licensing takes on prospects cast off in Pfizer’s recent exit from non-“high priority” therapeutic areas.
Drug makers need to continue investing in early-stage research to unveil the next $1 billion-plus drug, panelists at the Argyle conference agree.